Global Systemic Lupus Erythematosus Market, By Treatment Type (Antimalarial Drugs, Non-Steroidal Anti-Inflammatory Drugs, Cytotoxic and Immunosuppressive Drugs, Disease-Modifying Anti-Rheumatic Drugs, Monoclonal Antibodies, Anticoagulants, Biologics, Others), Diagnosis (Blood Tests, Urinalysis, Chest X-Ray), Dosage Form (Tablet, Capsule, Injection, Others), Route of Administration (Oral, Intravenous, Subcutaneous), Symptoms (Chest Pain, Fatigue, Swollen Lymph Nodes, Fever, General Discomfort, Uneasiness, Hair Loss, Weight Loss, Mouth Sores, Sensitivity to Sunlight, Skin Rash, Others), End-Users (Clinic, Hospital, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy), Country (U.S., Canada, Mexico, Brazil, Argentina, Peru, Rest of South America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific, Saudi Arabia, U.A.E, Egypt, Israel, Kuwait, South Africa, Rest of Middle East and Africa) Industry Trends and Forecast to 2029